Hillard T
Poole Hospital NHS Trust, Dorset, U.K.
Int J Fertil Womens Med. 1997;42 Suppl 2:347-64.
As knowledge about menopause and hormone replacement therapy (HRT) has increased, it has become evident that a considerably higher percentage of postmenopausal women than the 20% to 30% currently treated could receive HRT. It is equally clear, however, that HRT is not appropriate for every woman and that "one size fits all" management of menopausal women is not always suitable. This paper, therefore, reviews published prescribing and management guidelines for instituting and maintaining HRT and summarizes current information concerning factors to be considered before recommending HRT. When choosing candidates, special attention should be placed on individual patient factors. A thorough history is required to determine the presence of contraindications and the likelihood of potential benefits and risk factors. The hormone replacement regimen, hormone preparations, and dosage forms that best meet the specific needs of the individual woman should be offered. Before undertaking long-term therapy, the candidate should be informed of the established and likely benefits and the relative risks of hormone therapy, and that the magnitude of some risks has not yet been definitively determined. The final decision to use therapy should be made by the patient, guided by her physician, and based on her current symptoms and her relative likelihood of developing coronary artery disease, osteoporotic fractures, and cancer. The ancillary benefits, the common side effects of each regimen, the bleeding patterns to expect, and the type and frequency of clinical monitoring that will be necessary during therapy should also be considered.
随着对更年期和激素替代疗法(HRT)的了解不断增加,显而易见的是,可接受HRT治疗的绝经后女性比例远高于目前接受治疗的20%至30%。然而,同样清楚的是,HRT并不适用于每一位女性,“一刀切”地管理更年期女性并不总是合适的。因此,本文回顾了已发表的关于启动和维持HRT的处方及管理指南,并总结了在推荐HRT之前应考虑的因素的当前信息。在选择候选人时,应特别关注个体患者因素。需要全面了解病史,以确定是否存在禁忌症以及潜在益处和风险因素的可能性。应提供最能满足个体女性特定需求的激素替代方案、激素制剂和剂型。在进行长期治疗之前,应告知候选人激素治疗已确定的和可能的益处以及相对风险,并且某些风险的程度尚未最终确定。使用治疗的最终决定应由患者在医生的指导下,根据其当前症状以及患冠状动脉疾病、骨质疏松性骨折和癌症的相对可能性做出。还应考虑辅助益处、每种方案的常见副作用、预期的出血模式以及治疗期间所需的临床监测类型和频率。